Compare LGIH & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | EVO |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 934.1M |
| IPO Year | 2013 | N/A |
| Metric | LGIH | EVO |
|---|---|---|
| Price | $40.91 | $2.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $75.90 | $7.00 |
| AVG Volume (30 Days) | ★ 415.7K | 94.1K |
| Earning Date | 04-28-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,705,504,000.00 | N/A |
| Revenue This Year | $2.32 | $1.37 |
| Revenue Next Year | $17.94 | $10.05 |
| P/E Ratio | $487.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $2.31 |
| 52 Week High | $69.42 | $4.80 |
| Indicator | LGIH | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 36.25 |
| Support Level | $34.71 | $2.32 |
| Resistance Level | $41.50 | $3.78 |
| Average True Range (ATR) | 2.33 | 0.09 |
| MACD | -0.64 | -0.06 |
| Stochastic Oscillator | 1.03 | 6.44 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.